ExpreS2ion has today informed the market about the progress on the HER2 breast cancer vaccine candidate, ES2B-C001, but also announced that they will no longer pursue the development of a CMV candidate, a collaboration with Evaxion Biotech.

Pharma Equity Group: Udstedelse af konvertibelt lån

Gubra: Offentliggør positive data fra fase 1 MAD-resultater for GUBamy

Dagens aktienyheder med Agillic, Audientes, Ascelia Pharma og Pharma Equity Group.

Revenue from department store and hypermarket chains declined by 1% in February. The best performing product group was food, where sales remained at the level of the comparison period and which may have been negatively affected by delivery days but also by a few days of strikes in grocery stores.

With the growth in the Learning business and extensive efficiency program, we expect Sanoma's earnings to grow significantly in the coming years. Our confidence in the realization of earnings growth through revenue growth has strengthened, while the share valuation is moderate. These factors, together with the overall more moderate risk profile of Sanoma, constitute an attractive risk/reward ratio in our view.

Ascelia Pharma: Subscription price for warrant TO1 and terms for exercise

Pharma Equity Group (One-pager): Proof-of-Concept year 2025

SP Group is set to release its 2024 Annual Report on March 31, 2025. The same day at 03:00 PM, CEO Lars Bering  and CFO Tilde Kejlhof will present the results and answer questions from the audience in an online live event.

SP Group havde et udfordrende 2023, men fik vendt udviklingen i løbet af 2024 med en række stærke kvartalsrapporter. Derfor bliver det også interessant at få en opdatering fra selskabet når regnskabet for 4. kvartal 2024, og dermed årsrapporten for hele 2024 offentliggøres mandag d. 31. marts. Samme dag kl. 13.00 kan du høre ledelsens udlægning af hvordan 2024 blev afsluttet, og hvad der forventes af 2025, når vi har CEO Lars Bering og CFO Tilde Kejlhof igennem på et virtuelt event.

Dagens aktienyheder med Gubra, SP Group og Aktier med Friis.

SP Group har her til morgen offentliggjort årsregnskab for 2024, der viser en solid afslutning på året, om end væksten er mindre markant end i de tidligere kvartaler i 2024, da der allerede sås en bedring i SP Groups tal i Q4 2023, og dermed et sværere sammenligningsgrundlag. SP Group guider for en mere moderat omsætningsvækst i 2025 imens guidance på EBITDA-margin er på et uændret niveau.

Canatu's long-term potential remains unchanged and is one step closer, although growth this year may be modest due to timing issues in the reactor business.

Following Nykredits second extension of its bid to the shareholders of Spar Nord we have updated our one-pager on the bank including a peer group of the largest listed banks on Nasdaq Copenhagen.

I den uges Aktier i Vælten ser vi nærmere på de danske børsnoterede banker, hvor alle har aflagt årsregnskab for 2024, som for nogles tilfælde faktisk overgik rekordåret 2023.